# Preconditioning With a Combination of Thiotepa, Cyclophosphamide, and Busulfan for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of NK/T-Cell Lymphoma

> **NCT07276737** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 37 (estimated)

## Conditions studied

- NK T-Cell Lymphoma

## Interventions

- **DRUG:** Thiotepa

## Key facts

- **NCT ID:** NCT07276737
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-30
- **Primary completion:** 2029-12-30
- **Final completion:** 2029-12-30
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07276737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07276737, "Preconditioning With a Combination of Thiotepa, Cyclophosphamide, and Busulfan for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of NK/T-Cell Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07276737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*